Triple-negative breast cancer: molecular characterization and targeted therapies
作者： Allen Nicholson , Jennifer Bishop , Donald Lannin , Brigid Killelea , Xiaojia Guo
DOI: 10.2217/BMT.13.40
关键词: Oncology 、 Cancer genome 、 Tumor heterogeneity 、 Bioinformatics 、 Molecular targets 、 Clinical trial 、 Internal medicine 、 Triple-negative breast cancer 、 Breast cancer 、 Medicine
摘要: SUMMARY Triple-negative breast cancer is an aggressive subtype of that does not have targeted therapies available. Recent research has focused on extensive molecular characterization in order to identify therapeutic targets. The Cancer Genome Atlas Network recently published one the most reviews date and identified modules related mutations, some which been clinical trials. Due tumor heterogeneity, it unlikely a single therapy will be effective. Identification targets tailored treatments based alterations individual cancers hold best promise for improving outcomes this cancer.
ed.ac.uk
futuremedicine.com
sci-hub.se 参考文章(105)
Shannon Puhalla, Jorge Rios, PARP Inhibitors in Breast Cancer: BRCA and Beyond Oncology. ,vol. 25, pp. 1014- ,(2011)
Zhiyuan Hu, Cheng Fan, Daniel S Oh, JS Marron, Xiaping He, Bahjat F Qaqish, Chad Livasy, Lisa A Carey, Evangeline Reynolds, Lynn Dressler, Andrew Nobel, Joel Parker, Matthew G Ewend, Lynda R Sawyer, Junyuan Wu, Yudong Liu, Rita Nanda, Maria Tretiakova, Alejandra Ruiz Orrico, Donna Dreher, Juan P Palazzo, Laurent Perreard, Edward Nelson, Mary Mone, Heidi Hansen, Michael Mullins, John F Quackenbush, Matthew J Ellis, Olufunmilayo I Olopade, Philip S Bernard, Charles M Perou, The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics. ,vol. 7, pp. 96- 96 ,(2006) , 10.1186/1471-2164-7-96
J. O'Shaughnessy, D. Miles, R. J. Gray, V. Dieras, E. A. Perez, R. Zon, J. Cortes, X. Zhou, S. Phan, K. Miller, A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). Journal of Clinical Oncology. ,vol. 28, pp. 1005- 1005 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.1005
L. A. Carey, H. S. Rugo, P. K. Marcom, W. Irvin, M. Ferraro, E. Burrows, X. He, C. M. Perou, E. P. Winer, TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer Journal of Clinical Oncology. ,vol. 26, pp. 1009- 1009 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.1009
S. J. Isakoff, P. E. Goss, E. L. Mayer, T. A. Traina, L. A. Carey, K. Krag, H. S. Rugo, M. C. Liu, V. Stearns, S. E. Come, D. R. Borger, C. A. Quadrino, D. Finkelstein, J. E. Garber, P. D. Ryan, E. P. Winer, L. W. Ellisen, , TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. Journal of Clinical Oncology. ,vol. 29, pp. 1025- 1025 ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.1025
S. J. Isakoff, B. Overmoyer, N. M. Tung, R. S. Gelman, V. L. Giranda, K. M. Bernhard, K. R. Habin, L. W. Ellisen, E. P. Winer, P. E. Goss, A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. Journal of Clinical Oncology. ,vol. 28, pp. 1019- 1019 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.1019
Bernd Gerber, Gunter von Minckwitz, Heinrich Stehle, Toralf Reimer, Ricardo Felberbaum, Nikolai Maass, Dorothea Fischer, Harald L. Sommer, Bettina Conrad, Olaf Ortmann, Tanja Fehm, Mahdi Rezai, Keyur Mehta, Sibylle Loibl, Effect of Luteinizing Hormone–Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study Journal of Clinical Oncology. ,vol. 29, pp. 2334- 2341 ,(2011) , 10.1200/JCO.2010.32.5704
Nancy U. Lin, Ann Vanderplas, Melissa E. Hughes, Richard L. Theriault, Stephen B. Edge, Yu-Ning Wong, Douglas W. Blayney, Joyce C. Niland, Eric P. Winer, Jane C. Weeks, Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network Cancer. ,vol. 118, pp. 5463- 5472 ,(2012) , 10.1002/CNCR.27581
Aye Aye Thike, Poh Yian Cheok, Ana Richelia Jara-Lazaro, Benita Tan, Patrick Tan, Puay Hoon Tan, Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer Modern Pathology. ,vol. 23, pp. 123- 133 ,(2010) , 10.1038/MODPATHOL.2009.145
Debu Tripathy, Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; May 30-June 3, 2008 Clinical Breast Cancer. ,vol. 8, pp. 313- 321 ,(2008) , 10.1016/S1526-8209(11)70524-9